Nuvectis Pharma, Inc. (NVCT)
| Market Cap | 767.62M +391.1% |
| Revenue (ttm) | n/a |
| Net Income | -30.28M |
| EPS | -1.30 |
| Shares Out | 32.58M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 196,956 |
| Open | 23.59 |
| Previous Close | 23.35 |
| Day's Range | 22.83 - 23.93 |
| 52-Week Range | 5.55 - 29.28 |
| Beta | -0.26 |
| Analysts | Strong Buy |
| Price Target | 34.20 (+45.16%) |
| Earnings Date | Aug 4, 2026 |
About NVCT
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is base... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for NVCT stock is "Strong Buy." The 12-month stock price target is $34.2, which is an increase of 45.16% from the latest price.
News
Nuvectis Pharma files $200M mixed securities shelf
16:39 EDT Nuvectis Pharma (NVCT) files $200M mixed securities shelf
Nuvectis Pharma Registration statement: Registration filing
Nuvectis Pharma filed a registration statement on August 21, 2026, providing details about a securities offering with the SEC.
Nuvectis Pharma Slides: Corporate presentation
Nuvectis Pharma has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Nuvectis Pharma price target raised to $34 from $22 at Lucid Capital
Lucid Capital analyst Christopher Liu raised the firm’s price target on Nuvectis Pharma (NVCT) to $34 from $22 and keeps a Buy rating on the shares post the Q2 report.
Nuvectis Pharma Earnings release: Q2 2026
Nuvectis Pharma released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
Nuvectis Pharma Quarterly report: Q2 2026
Nuvectis Pharma has published its Q2 2026 quarterly earnings report on August 4, 2026.
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovativ...
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
First global approval of a once-daily, orally administered, Complement Factor B inhibitor Approval based on robust efficacy and safety data from Haisco's broad completed clinical development program i...
Nuvectis Pharma receives marketing approval in China for ciprocopan
Nuvectis Pharma (NVCT) announced that ciprocopan, a once-daily oral complement Factor B inhibitor, received marketing approval from the National Medicinal Products Administration of China, or NMPA, fo...
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative ...
StreetWatch: Nuvectis Pharma Eyes $9.8 Billion Oral PNH Market With Late-Stage NXP100 Backed by Strong Positive Phase 3 Data
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncology story into a late-stage rare-disease player following its June licensing deal with Haisco Pharma...
Nuvectis Pharma price target raised to $33 from $20 at Roth Capital
Roth Capital raised the firm’s price target on Nuvectis Pharma (NVCT) to $33 from $20 and keeps a Buy rating on the shares. The company “significantly improved” its clinical-stage pipeline…
Nuvectis Pharma 5M share Spot Secondary priced at $20.00
The deal range was $20.00-$22.00. Cantor Fitzgerald acted as sole book running manager for the offering.
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment ...
Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00
Cantor Fitzgerald is acting as sole book running manager for the offering.
Nuvectis Pharma announces common stock offering, no amount given
Nuvectis Pharma (NVCT) announced that it has commenced an underwritten public offering of its common stock. All of the shares to be sold in the offering will be offered by…
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of...
Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital
Lucid Capital analyst Christopher Liu raised the firm’s price target on Nuvectis Pharma (NVCT) to $22 from $18 and keeps a Buy rating on the shares. The company announced a…
Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nuvectis Pharma (NVCT) to $39 from $13 and keeps a Buy rating on the shares. The firm says the company’s licensing agreement…
Nuvectis gains two experimental drugs in licensing deal with China's Haisco
Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental drugs from Haisco Pharmaceutical Group , targeting complement-mediated diseases and cancer to broaden...
Nuvectis Pharma Transcript: Status update
A transformative in-licensing deal brings two late-stage drug candidates, NXP100 and NXP200, into the pipeline, expanding focus to complement-mediated diseases and oncology. NXP100 offers once-daily oral dosing with strong efficacy, while NXP200 shows promise in multiple tumor types.
Nuvectis Pharma Press release: Status update
Nuvectis Pharma issued a press release on June 22, 2026, disclosing material business information to investors.
Nuvectis Pharma announces license agreement with Haisco for two compounds
Nuvectis Pharma (NVCT) announced a strategic portfolio expansion via a license agreement for exclusive ex-China rights with Haisco Pharmaceutical to two clinical-stage compounds. NXP100 is a once-dail...
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Potentially Best-In Class Clinical-Stage Compounds
Fort Lee, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of innovative ...
Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Nuvectis Pharma (NVCT) to $13 from $10 and keeps a Buy rating on the shares. The firm increased its probability of success…